In solid tumors such as malignant melanoma, colorectal cancer and breast cancer, FLT3LG can increase immune cell activity and elicit antitumor responses through the use of diverse modalities, such as plasmids, adenoviruses, vaccines, and adjuvants [19–23]. This evidence concerns the gene FLT3LG and breast carcinoma.